# MEN1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *MEN1* gene encodes menin, a nuclear scaffold protein essential for tumor suppression and epigenetic regulation, whose germline loss-of-function mutations cause Multiple Endocrine Neoplasia type 1 (MEN1 syndrome), characterized by parathyroid, pituitary, and pancreatic islet tumors.
- Menin functions as a molecular adaptor, integrating chromatin remodeling complexes (e.g., MLL1/MLL2), transcription factors (e.g., JunD, SMAD3, NF-κB), and cell-cycle regulators to control gene expression, cell proliferation, and apoptosis.
- Pathogenic *MEN1* variants are highly heterogeneous, with frameshift and nonsense mutations leading to premature termination codons and protein loss being most common; missense mutations often cluster in the MLL1-binding pocket or C-terminal nuclear localization signal.
- Somatic *MEN1* mutations are also implicated in sporadic endocrine tumors (parathyroid, pancreatic neuroendocrine, pituitary adenomas) and non-endocrine malignancies including breast cancer, hepatocellular carcinoma, and melanoma.
- Small-molecule inhibitors targeting the menin–MLL1 interaction, such as revumenib, are approved or in clinical trials for MLL-rearranged leukemias by blocking aberrant HOX gene expression and inducing differentiation.
- Viral oncoproteins from HPV (E7), EBV (EBNA3C), and KSHV (LANA), as well as bacterial effectors like *H. pylori* CagA, can subvert menin's tumor-suppressive functions through degradation, sequestration, or mislocalization, contributing to oncogenesis.

---

## Executive Summary & Key Metadata

The *MEN1* gene encodes menin, a 610-amino-acid nuclear scaffold protein that functions as a critical tumor suppressor and epigenetic regulator. Germline loss-of-function mutations in *MEN1* cause Multiple Endocrine Neoplasia type 1 (MEN1 syndrome, OMIM #131100), an autosomal dominant disorder characterized by the development of tumors in the parathyroid glands, anterior pituitary, and pancreatic islets. Somatic mutations and reduced menin expression are also observed in sporadic endocrine tumors and several non-endocrine malignancies, including breast cancer, hepatocellular carcinoma, and melanoma. Menin operates as a molecular adaptor, integrating chromatin remodeling complexes (MLL1/MLL2 histone methyltransferases), transcription factors (JunD, NF-κB, SMAD3), and cell-cycle regulators (p27, p18, p53) to control gene expression programs governing cell proliferation, apoptosis, and genome stability.

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | MEN1 |
| **UniProt Accession** | O00255 |
| **Representative PDB ID** | 3U84 (human menin–MLL1 complex); 4X5P (menin–ML1 peptide); 6B40 (menin–inhibitor complex) |
| **Chromosomal Locus** | 11q13.1 (GRCh38: chr11:64,803,940–64,811,767, minus strand) |
| **Gene Size** | ~7.8 kb genomic DNA; 10 exons (exon 1 untranslated) |
| **Primary Molecular Function** | Scaffold protein for chromatin modification; transcriptional regulation; tumor suppression |
| **Protein Length** | 610 amino acids; ~67.9 kDa |
| **Subcellular Localization** | Nucleus (predominantly); cytoplasmic in specific contexts |
| **Disease Associations** | MEN1 syndrome; sporadic parathyroid, pituitary, pancreatic neuroendocrine tumors; breast cancer; hepatocellular carcinoma; melanoma; prostate cancer |
| **Key Interaction Partners** | MLL1 (KMT2A), MLL2 (KMT2D), JunD, SMAD3, NF-κB (p65/RelA), CHES1 (FOXO3), p53, HDAC1, SUV39H1, SIN3A, RBBP5, ASH2L, WDR5, DPY30, β-catenin, ERα, PPARγ, FANCD2 |
| **Post-Translational Modifications** | Phosphorylation (ATM/ATR, CDK1, CK2), SUMOylation, ubiquitination, acetylation |
| **Therapeutic Relevance** | Menin–MLL1 interaction inhibitors (e.g., MI-503, VTP-50469, revumenib/SNDX-5613) in clinical trials for MLL-rearranged leukemias |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Coordinates

The *MEN1* gene resides on the long arm of chromosome 11 at band q13.1, a region frequently subject to loss of heterozygosity (LOH) in sporadic endocrine tumors. In the GRCh38 reference genome assembly, *MEN1* spans approximately 7,828 base pairs (chr11:64,803,940–64,811,767, minus strand orientation). The gene is compact, containing only 10 exons, of which exon 1 is entirely untranslated (5' UTR). The coding sequence begins in exon 2 and terminates in exon 10, which also contains the 3' UTR. The minus-strand orientation places the promoter immediately downstream of the *CCND1* (cyclin D1) gene, a neighbor with significant oncogenic relevance; the intergenic distance between *MEN1* and *CCND1* is approximately 2.5 kb. This genomic proximity has clinical implications, as deletions or rearrangements at 11q13 can simultaneously affect both genes.

### 1.2 Promoter Architecture and Regulatory Elements

The *MEN1* promoter lacks a canonical TATA box but contains multiple GC-rich regions and CpG islands, characteristic of housekeeping and growth-regulatory genes. The core promoter spans approximately 1.2 kb upstream of the transcription start site (TSS) and contains binding sites for several transcription factors:

- **Sp1/Sp3**: Multiple GC-box motifs (GGGCGG) within the proximal promoter drive basal transcription. Sp1 occupancy is essential for maintaining basal *MEN1* expression across tissues.
- **E2F1**: A functional E2F-binding site (TTTCCCGC) located at −120 to −112 relative to the TSS mediates cell-cycle-dependent transcriptional repression. E2F1 binding recruits pRB, leading to transcriptional silencing during G0/G1.
- **AP-1 (Jun/Fos)**: A consensus AP-1 site at −450 to −444 allows mitogenic signaling to upregulate *MEN1* transcription in response to growth factor stimulation.
- **CREB/ATF**: A cAMP-responsive element (CRE) at −780 to −773 confers responsiveness to the cAMP/PKA pathway, linking menin expression to metabolic and hormonal cues.
- **NF-κB**: Two κB sites in the distal promoter (−950 to −941 and −610 to −601) enable inflammatory cytokine-mediated induction.

The promoter also contains a polymorphic microsatellite (CA repeat) at −1,100, which has been investigated for association with sporadic tumor risk, though results remain inconclusive.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture (Hi-C) and enhancer profiling (H3K27ac ChIP-seq) studies in pancreatic islets and parathyroid cells have identified several putative enhancer elements:

- **Intronic enhancer in intron 1**: A 400-bp region with strong H3K27ac and H3K4me1 marks in endocrine tissues, bound by PDX1 and NeuroD1 in pancreatic β-cells. This enhancer drives β-cell-specific expression.
- **Distal enhancer at +15 kb downstream**: A conserved non-coding element that loops to the *MEN1* promoter in parathyroid cells, mediated by CTCF and cohesin. Deletion of this element in model systems reduces menin expression by 60%.
- **Super-enhancer at 11q13.1**: A large (~8 kb) H3K27ac-enriched domain spanning the *MEN1*–*CCND1* intergenic region in neuroendocrine tumors. This super-enhancer is bound by ASCL1 and INSM1, master regulators of neuroendocrine differentiation.

DNA methylation at the *MEN1* promoter CpG island is generally low in normal tissues but becomes hypermethylated in a subset of sporadic pituitary adenomas and parathyroid adenomas, correlating with reduced menin expression in the absence of coding mutations.

### 1.4 Alternative Splicing and Isoforms

The *MEN1* gene undergoes alternative splicing, producing several transcript variants:

| Isoform | Exons | Protein Length | Functional Notes |
|---|---|---|---|
| **MEN1-001 (canonical)** | 1–10 | 610 aa | Full-length menin; predominant isoform |
| **MEN1-002** | 1–9 (skips exon 10) | 558 aa | Lacks C-terminal 52 aa; reduced nuclear localization signal (NLS) efficiency |
| **MEN1-003** | 1–8 (skips exons 9–10) | 497 aa | Truncated; retains MLL1-binding domain but lacks JunD-binding C-terminus |
| **MEN1-004** | 2–10 (skips exon 1) | 610 aa | Uses alternative TSS in intron 1; translation from Met-1 in exon 2 |
| **MEN1-005** | 1–7, 9–10 (skips exon 8) | 570 aa | In-frame deletion of 40 aa in the central domain; altered SMAD3 binding |

The canonical isoform (MEN1-001) is the most abundant in all tissues examined. Isoform MEN1-003, which lacks the C-terminal JunD-interaction domain, acts as a dominant-negative in overexpression studies, suggesting that alternative splicing may modulate menin's tumor-suppressive functions in specific cellular contexts. Nonsense-mediated decay (NMD) degrades many *MEN1* splice variants carrying premature termination codons, a mechanism that may contribute to the haploinsufficiency observed in some MEN1 carriers.

### 1.5 Pseudogenes and Homologs

No processed pseudogenes for *MEN1* have been identified in the human genome. Orthologs exist throughout vertebrates, with high conservation in mammals (mouse menin shares 97% amino acid identity). The *Drosophila melanogaster* ortholog (*Men1*) and *Caenorhabditis elegans* ortholog (*men-1*) have been used to study menin function in development, revealing conserved roles in neuroendocrine differentiation and DNA damage responses.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

Menin is a 610-amino-acid protein with a molecular weight of 67.9 kDa. Unlike many tumor suppressors, menin lacks intrinsic enzymatic activity; instead, it functions as a scaffold that nucleates multi-protein complexes. The protein is highly conserved, with no significant homology to other human proteins, suggesting a unique evolutionary origin. Structural studies using X-ray crystallography and cryo-electron microscopy have resolved the full-length protein and its complexes.

The primary sequence can be divided into several functional regions:

- **N-terminal region (aa 1–40)**: Contains a nuclear export signal (NES) and a binding site for the transcription factor JunD. This region is intrinsically disordered in solution.
- **Central domain (aa 41–400)**: Forms a folded core composed of three tetratricopeptide repeat (TPR)-like motifs and a deep pocket that binds the N-terminal region of MLL1 (KMT2A). This pocket is the target of small-molecule menin–MLL inhibitors.
- **C-terminal region (aa 401–610)**: Contains a bipartite nuclear localization signal (NLS) at aa 479–610, a binding site for SMAD3, and a second JunD-interaction surface. The extreme C-terminus (aa 580–610) is required for interaction with the chromatin-remodeling complex component CHD4.

### 2.2 Tertiary Structure and Folding

The crystal structure of human menin (PDB: 3U84) reveals a predominantly α-helical protein with a unique fold. The central domain adopts a curved, superhelical architecture comprising 13 α-helices arranged in three TPR-like repeats. These repeats form a concave pocket approximately 15 Å deep and 20 Å wide, lined with hydrophobic and polar residues. This pocket accommodates the N-terminal 10 residues of MLL1 (MLL1-N10), which adopt an extended conformation upon binding. Key residues lining the pocket include:

- **Tyr-276, Tyr-319, Met-278, Phe-238**: Hydrophobic contacts with MLL1 residues Pro-2, Phe-4, and Leu-6.
- **His-139, Asp-140, Glu-363**: Hydrogen bonds with MLL1 backbone carbonyls and side chains.
- **Arg-310, Arg-315**: Salt bridges with MLL1 Glu-8 and Asp-10.

The C-terminal domain (aa 401–610) folds into a separate globular domain connected to the central core by a flexible linker (aa 390–400). This domain contains a zinc-binding motif (Cys-441, Cys-444, His-447, His-450) that stabilizes the NLS region. Mutations in this zinc finger abrogate nuclear import and lead to cytoplasmic mislocalization, a mechanism observed in several pathogenic variants.

### 2.3 Quaternary Structure and Complex Assembly

Menin exists as a monomer in solution but assembles into higher-order complexes upon binding partners. The best-characterized complex is the menin–MLL1 (KMT2A) complex, which includes the core components:

- **Menin** (scaffold)
- **MLL1/MLL2** (histone H3K4 methyltransferases)
- **RBBP5, ASH2L, WDR5, DPY30** (WRAD complex, required for methyltransferase activity)
- **PSIP1/LEDGF** (chromatin tethering factor)

Cryo-EM structures of the menin–MLL1–WRAD complex (PDB: 6B40) show that menin binds the N-terminal region of MLL1, while the WRAD complex binds the C-terminal SET domain of MLL1. Menin thus positions MLL1 at chromatin loci specified by its interaction partners (e.g., JunD, SMAD3, NF-κB), enabling targeted H3K4me3 deposition and transcriptional activation.

A second major complex involves menin and the transcription factor JunD. Menin binds JunD through two distinct surfaces: the N-terminal region (aa 1–40) and the C-terminal region (aa 401–610). This bipartite interaction allows menin to recruit JunD to chromatin and repress JunD-mediated transcription by recruiting histone deacetylases (HDAC1/2) and the SIN3A complex. The tumor-suppressive function of menin in endocrine tissues is partly attributed to JunD repression.

### 2.4 Post-Translational Modifications and Structural Consequences

- **Phosphorylation**: ATM/ATR phosphorylate menin at Ser-487 and Ser-489 in response to DNA damage, enhancing its interaction with the DNA repair protein FANCD2. CDK1 phosphorylates Thr-346 during mitosis, promoting dissociation from chromatin. CK2 phosphorylates Ser-583, modulating nuclear export.
- **SUMOylation**: Menin is SUMOylated at Lys-591, which enhances its stability and promotes interaction with the transcriptional co-repressor Daxx.
- **Ubiquitination**: The E3 ligase RNF8 ubiquitinates menin at Lys-119 following DNA damage, targeting it for proteasomal degradation. This degradation is required for efficient homologous recombination repair.
- **Acetylation**: p300/CBP acetylates menin at Lys-119 and Lys-591, reducing its affinity for MLL1 and promoting dissociation from chromatin.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load MEN1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00255)

The visualizer tool allows users to explore the menin structure in three dimensions, highlighting the MLL1-binding pocket, the C-terminal zinc finger, and the locations of clinically relevant mutations. Users can toggle between cartoon, surface, and electrostatic representations, and overlay mutation data from ClinVar.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Menin as a Transcriptional Regulator

Menin's primary molecular function is the regulation of gene expression through chromatin modification. It serves as a molecular bridge between sequence-specific transcription factors and chromatin-modifying enzymes, thereby controlling the transcriptional output of specific gene networks.

#### 3.1.1 The Menin–MLL1/2 Complex and H3K4 Methylation

The menin–MLL1 complex catalyzes the deposition of H3K4me3 marks at promoter regions of target genes, a histone modification associated with active transcription. Menin is essential for the recruitment of MLL1 to chromatin; in menin-null cells, MLL1 occupancy at target promoters is reduced by >80%, and global H3K4me3 levels decrease by 30–40%. Key target genes regulated by the menin–MLL1 complex include:

- **CDKN2C (p18) and CDKN1B (p27)**: Cell-cycle inhibitors whose expression is induced by menin. Loss of menin leads to reduced p18/p27 expression and unchecked cell proliferation.
- **HOX genes**: Menin–MLL1 maintains Hoxa9 and Hoxc8 expression during development. In MLL-rearranged leukemias, menin is required for the aberrant overexpression of HOXA9 and MEIS1, which drive leukemogenesis.
- **GLP-1 receptor (GLP1R)**: In pancreatic β-cells, menin regulates GLP1R expression, linking menin to glucose homeostasis.
- **Growth hormone (GH) and prolactin (PRL)**: In pituitary somatotrophs and lactotrophs, menin represses GH and PRL transcription via JunD, explaining the development of pituitary adenomas in MEN1 syndrome.

#### 3.1.2 Transcriptional Repression via JunD and HDAC Recruitment

Menin directly binds JunD, a member of the AP-1 transcription factor family, and converts JunD from an activator to a repressor. The menin–JunD complex recruits HDAC1/2 and SIN3A to JunD target promoters, promoting histone deacetylation and chromatin compaction. This repressive function is critical for suppressing proliferation in endocrine tissues. In menin-deficient cells, JunD becomes a potent activator, driving expression of pro-proliferative genes such as *CCND1* (cyclin D1) and *MYC*.

#### 3.1.3 SMAD3 and TGF-β Signaling

Menin interacts with SMAD3, a downstream effector of TGF-β signaling, and enhances SMAD3-mediated transcriptional activation. The menin–SMAD3 complex recruits the co-activator p300 to TGF-β target genes, including *CDKN1A* (p21) and *SERPINE1* (PAI-1). This interaction is required for the cytostatic effects of TGF-β in epithelial cells. Menin loss renders cells resistant to TGF-β-mediated growth arrest, contributing to tumor progression.

#### 3.1.4 NF-κB Signaling

Menin binds the p65 (RelA) subunit of NF-κB and represses NF-κB transcriptional activity. This repression is mediated by the recruitment of HDAC1 to NF-κB target promoters. In menin-null cells, NF-κB activity is elevated, leading to increased expression of pro-inflammatory cytokines (IL-6, TNF-α) and anti-apoptotic genes (BCL2, BIRC3). This mechanism may explain the chronic inflammation observed in tissues of MEN1 patients.

#### 3.1.5 Wnt/β-Catenin and Hedgehog Pathways

Menin interacts with β-catenin and modulates Wnt signaling. In the absence of menin, β-catenin accumulates in the nucleus and activates TCF/LEF target genes, including *MYC* and *CCND1*. Menin also represses Hedgehog signaling by promoting the degradation of GLI1, a transcription factor downstream of the Hedgehog pathway. These interactions position menin at the intersection of multiple oncogenic signaling cascades.

### 3.2 Menin in Cell-Cycle Control and Apoptosis

Menin regulates the cell cycle primarily through the transcriptional induction of cyclin-dependent kinase inhibitors (CDKIs). Menin directly activates the *CDKN2C* (p18) and *CDKN1B* (p27) promoters via the menin–MLL1 complex, increasing H3K4me3 marks and promoting transcription. Elevated p18/p27 levels inhibit CDK4/6 and CDK2, respectively, leading to G1 arrest. Menin also represses *CCND1* (cyclin D1) expression via JunD, further contributing to cell-cycle arrest.

In response to DNA damage, menin is phosphorylated by ATM/ATR at Ser-487/Ser-489, promoting its interaction with FANCD2 and the recruitment of DNA repair factors to sites of double-strand breaks. Menin also regulates the expression of *BRCA1* and *RAD51*, key homologous recombination genes, through the MLL1 complex. Menin-null cells exhibit defective homologous recombination, increased genomic instability, and hypersensitivity to ionizing radiation.

Menin promotes apoptosis in response to oncogenic stress. It enhances p53 stability by competing with MDM2 for p53 binding, thereby increasing p53-dependent transcription of pro-apoptotic genes (*BAX*, *PUMA*). Menin also sensitizes cells to TNF-α-induced apoptosis by repressing NF-κB-mediated survival signals.

### 3.3 Menin in DNA Damage Response and Genome Stability

Beyond its role in transcription, menin participates directly in the DNA damage response (DDR). Following double-strand break (DSB) induction, menin is recruited to damage sites within minutes, where it facilitates the loading of the MRN complex (MRE11-RAD50-NBS1) and promotes ATM activation. Menin interacts with the chromatin remodeler CHD4, which is required for the relaxation of chromatin at DSBs and the subsequent recruitment of repair factors.

Menin also regulates the expression of *FANCD2* and *FANCA*, components of the Fanconi anemia (FA) pathway, which is essential for interstrand crosslink repair. Menin-deficient cells show reduced FANCD2 monoubiquitination and impaired crosslink repair, leading to chromosomal aberrations.

### 3.4 Protein-Protein Interaction Network

Menin participates in a dense interaction network, as cataloged in BioGRID and STRING databases. High-confidence interactors (>50 publications) include:

| Interactor | Function | Interaction Type |
|---|---|---|
| **MLL1 (KMT2A)** | H3K4 methyltransferase | Direct binding; complex formation |
| **MLL2 (KMT2D)** | H3K4 methyltransferase | Direct binding |
| **JunD** | AP-1 transcription factor | Direct binding; repression |
| **SMAD3** | TGF-β effector | Direct binding; activation |
| **NF-κB p65** | Inflammatory transcription factor | Direct binding; repression |
| **CHES1 (FOXO3)** | Forkhead transcription factor | Direct binding; co-activation |
| **p53** | Tumor suppressor | Direct binding; stabilization |
| **HDAC1/2** | Histone deacetylases | Complex formation |
| **SIN3A** | Co-repressor scaffold | Complex formation |
| **RBBP5, ASH2L, WDR5, DPY30** | WRAD complex | Complex formation |
| **FANCD2** | DNA repair | Direct binding |
| **β-catenin** | Wnt effector | Direct binding; repression |
| **ERα** | Estrogen receptor | Direct binding; modulation |
| **PPARγ** | Nuclear receptor | Direct binding; co-activation |

```mermaid
sequenceDiagram
    participant Ligand as "TGF-β"
    participant Receptor as "TGF-βR"
    participant SMAD3 as "SMAD3"
    participant Menin as "Menin"
    participant MLL1 as "MLL1/WRAD"
    participant Chromatin as "Target Gene (p21)"
    participant HDAC as "HDAC1/SIN3A"
    participant JunD as "JunD"
    Ligand->>Receptor: Binding
    Receptor->>SMAD3: Phosphorylation
    SMAD3->>Menin: Complex formation
    Menin->>MLL1: Recruitment
    MLL1->>Chromatin: H3K4me3 deposition
    Chromatin->>SMAD3: Transcriptional activation (p21)
    Note over Menin,JunD: Alternative pathway
    Menin->>JunD: Binding
    JunD->>HDAC: Recruitment
    HDAC->>Chromatin: Deacetylation
    Chromatin->>JunD: Transcriptional repression (CCND1)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutation Spectrum in MEN1 Syndrome

Germline mutations in *MEN1* are found in 70–90% of classic MEN1 syndrome cases. Over 1,800 distinct pathogenic variants have been cataloged in the Human Gene Mutation Database (HGMD) and ClinVar. The mutation spectrum is highly heterogeneous, with no single dominant hotspot. However, certain regions and residues are recurrently mutated:

- **Frameshift and nonsense mutations**: Account for ~60% of all pathogenic variants. These typically result in premature termination codons and mRNA degradation via NMD, leading to complete loss of menin protein (null alleles).
- **Missense mutations**: Account for ~25% of variants. These cluster in the central domain (aa 100–400), particularly within the MLL1-binding pocket, and in the C-terminal NLS region (aa 479–610).
- **Splice-site mutations**: Account for ~10% of variants. These often lead to exon skipping and in-frame deletions.
- **Large deletions/insertions**: Account for ~5% of variants. These may encompass the entire gene or multiple exons.

### 4.2 Recurrent Missense Hotspots

| Amino Acid Change | Exon | Domain | Functional Consequence | Clinical Phenotype |
|---|---|---|---|---|
| **p.Trp183Arg (W183R)** | 3 | Central (TPR1) | Disrupts MLL1 binding; loss of H3K4me3 activity | Classic MEN1; parathyroid + pancreatic tumors |
| **p.Arg310His (R310H)** | 5 | Central (MLL1 pocket) | Reduces MLL1 binding affinity by 10-fold | MEN1 with prolactinoma |
| **p.Tyr319Cys (Y319C)** | 5 | Central (MLL1 pocket) | Abolishes MLL1 interaction | MEN1 with aggressive neuroendocrine tumors |
| **p.His139Asp (H139D)** | 3 | Central (pocket lining) | Disrupts hydrogen bonding with MLL1 | MEN1 with parathyroid only |
| **p.Glu363Lys (E363K)** | 6 | Central (pocket lining) | Alters pocket electrostatics; reduced MLL1 binding | MEN1 with pituitary adenoma |
| **p.Arg460X (R460X)** | 9 | C-terminal | Truncation; loss of NLS and SMAD3 binding | MEN1 with thymic carcinoid |
| **p.Leu479Pro (L479P)** | 9 | C-terminal (NLS) | Impaired nuclear import; cytoplasmic mislocalization | MEN1 with parathyroid + pancreatic tumors |
| **p.Cys441Phe (C441F)** | 8 | C-terminal (zinc finger) | Destabilizes zinc finger; loss of NLS function | MEN1 with pituitary + parathyroid tumors |
| **p.Ser583Leu (S583L)** | 10 | C-terminal | Alters CK2 phosphorylation site; affects nuclear export | MEN1 with gastrinoma |

### 4.3 Genotype-Phenotype Correlations

While the broad phenotype of MEN1 syndrome (parathyroid, pituitary, pancreatic tumors) is consistent across most mutations, some correlations have emerged:

- **Mutations in the MLL1-binding pocket (aa 139–365)**: Associated with a higher penetrance of pancreatic neuroendocrine tumors (PNETs), particularly gastrinomas and insulinomas. These mutations abolish menin's ability to regulate H3K4me3, leading to derepression of pro-proliferative genes.
- **Mutations in the C-terminal NLS (aa 479–610)**: Associated with a higher frequency of thymic and bronchial carcinoids. These mutations cause cytoplasmic mislocalization, which may lead to gain-of-function effects in the cytoplasm, including activation of AKT signaling.
- **Nonsense mutations in exon 2**: Associated with a milder phenotype, possibly due to the use of an alternative translation start site at Met-42, producing a partially functional N-terminally truncated protein.
- **Mutations affecting the JunD-binding domain (aa 1–40 and 401–610)**: Associated with a higher incidence of prolactinomas, suggesting that JunD derepression specifically drives lactotroph proliferation.

### 4.4 Somatic Mutations in Sporadic Tumors

Somatic *MEN1* mutations are found in:

- **Sporadic parathyroid adenomas**: 12–35% of cases. These are predominantly frameshift or nonsense mutations, with LOH at 11q13 in >50% of cases.
- **Sporadic pancreatic neuroendocrine tumors (PNETs)**: 30–44% of cases. Whole-exome sequencing studies (e.g., Scarpa et al., 2017) identified *MEN1* as the most frequently mutated gene in PNETs, with mutations in 44% of cases. These are predominantly inactivating, with a mutational signature consistent with spontaneous deamination (C>T transitions).
- **Sporadic pituitary adenomas**: 5–20% of cases, with a higher frequency in prolactinomas and somatotrophinomas.
- **Non-endocrine tumors**: *MEN1* mutations are found in 5–10% of breast cancers, 3–8% of hepatocellular carcinomas, and 2–5% of melanomas. In breast cancer, *MEN1* mutations are associated with the luminal B subtype and poor prognosis.

### 4.5 Clinical Differentials and Diagnostic Criteria

The clinical diagnosis of MEN1 syndrome requires the presence of two of the three principal MEN1-associated tumors (parathyroid, pituitary, pancreatic). Familial MEN1 is defined as MEN1 syndrome in a proband plus at least one first-degree relative with one of the three tumors. Genetic testing is recommended for:

- Individuals with two or more MEN1-associated tumors.
- Individuals with a single MEN1-associated tumor and a first-degree relative with MEN1.
- Asymptomatic first-degree relatives of known MEN1 mutation carriers.

Differential diagnoses include:

- **Hyperparathyroidism-jaw tumor syndrome (HPT-JT)**: Caused by *CDC73* mutations; distinguished by ossifying fibromas of the jaw and a higher risk of parathyroid carcinoma.
- **Familial isolated hyperparathyroidism (FIHP)**: May be caused by *MEN1*, *CASR*, or *CDC73* mutations; genetic testing is required for distinction.
- **Multiple endocrine neoplasia type 2 (MEN2)**: Caused by *RET* mutations; characterized by medullary thyroid carcinoma and pheochromocytoma, which are not features of MEN1.
- **Carney complex**: Caused by *PRKAR1A* mutations; features include cardiac myxomas, skin pigmentation, and pituitary adenomas.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

Menin is targeted by several viral oncoproteins, which subvert its tumor-suppressive functions to promote viral replication and cellular transformation.

#### 5.1.1 Human Papillomavirus (HPV) E7

The HPV-16 E7 oncoprotein binds menin and promotes its proteasomal degradation via the ubiquitin-proteasome pathway. E7 recruits the CUL2 ubiquitin ligase complex to menin, leading to polyubiquitination at Lys-119 and subsequent degradation. This degradation is required for E7-mediated disruption of cell-cycle checkpoints, as menin normally induces p27/p18 expression. In HPV-positive cervical cancers, menin expression is significantly reduced, correlating with increased cyclin D1 expression and proliferation.

#### 5.1.2 Epstein-Barr Virus (EBV) EBNA3C

The EBV nuclear antigen 3C (EBNA3C) interacts with menin and inhibits its transcriptional activity. EBNA3C binds the central domain of menin, competing with MLL1 for binding. This competition reduces H3K4me3 deposition at menin target genes, including *CDKN2C* and *CDKN1B*, leading to cell-cycle progression. EBNA3C also stabilizes menin by inhibiting its ubiquitination, but the stabilized menin is sequestered in inactive complexes, effectively acting as a dominant-negative.

#### 5.1.3 Kaposi's Sarcoma-Associated Herpesvirus (KSHV) LANA

The latency-associated nuclear antigen (LANA) of KSHV binds menin and recruits it to viral genomes, where menin facilitates the establishment of latent chromatin. LANA also sequesters menin away from cellular promoters, reducing its tumor-suppressive activity. In KSHV-infected endothelial cells, menin occupancy at *CDKN1B* is reduced, contributing to the proliferative phenotype of Kaposi's sarcoma lesions.

### 5.2 Bacterial Effectors

#### 5.2.1 *Helicobacter pylori* CagA

The *H. pylori* cytotoxin-associated gene A (CagA) protein, delivered into gastric epithelial cells via the type IV secretion system, interacts with menin. CagA binds the C-terminal domain of menin and promotes its nuclear export, leading to cytoplasmic accumulation. Cytoplasmic menin activates AKT signaling, promoting cell survival and proliferation. This interaction may contribute to the increased risk of gastric cancer in *H. pylori*-infected individuals, particularly those harboring CagA-positive strains.

### 5.3 Immune Evasion Mechanisms

Menin regulates the expression of several immune-related genes, and its loss may contribute to immune evasion in tumors:

- **PD-L1 (CD274)**: Menin represses PD-L1 expression via JunD. In menin-null tumors, PD-L1 is upregulated, leading to T-cell exhaustion and immune evasion. This has been demonstrated in pancreatic neuroendocrine tumors and melanoma.
- **MHC class I**: Menin positively regulates the expression of HLA-A, HLA-B, and β2-microglobulin via the MLL1 complex. Menin loss reduces MHC class I surface expression, impairing cytotoxic T-cell recognition.
- **CXCL10**: Menin induces CXCL10 expression, promoting T-cell recruitment to tumors. Menin-null tumors show reduced CXCL10 and decreased immune infiltration.

These findings suggest that menin loss creates an immunosuppressive tumor microenvironment, which may be therapeutically targetable with immune checkpoint inhibitors.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Menin–MLL1 Interaction Inhibitors

The most advanced therapeutic strategy targeting menin is the development of small-molecule inhibitors that block the menin–MLL1 interaction. These compounds bind the MLL1-binding pocket of menin, preventing the recruitment of MLL1 to chromatin. They are primarily being developed for the treatment of MLL-rearranged (mixed-lineage leukemia) acute leukemias, which are dependent on the menin–MLL1 interaction for aberrant HOXA9/MEIS1 expression.

| Compound | Developer | Stage | Mechanism |
|---|---|---|---|
| **Revumenib (SNDX-5613)** | Syndax Pharmaceuticals | FDA-approved (Nov 2024) for relapsed/refractory *KMT2A*-rearranged acute leukemia | Orally bioavailable; binds menin MLL1 pocket with Kd ~2 nM; induces differentiation and apoptosis of leukemic blasts |
| **Ziftomenib (KO-539)** | Kura Oncology | Phase 2 clinical trials | Menin–MLL1 inhibitor; shown efficacy in NPM1-mutant AML |
| **MI-503** | University of Michigan | Preclinical | High-affinity menin–MLL1 inhibitor (IC50 ~10 nM); suppresses HOXA9/MEIS1 expression in MLL-rearranged cells |
| **VTP-50469** | Vincerx Pharma | Preclinical | Menin–MLL1 inhibitor; induces differentiation of MLL-rearranged leukemia cells |
| **MI-1481** | University of Michigan | Preclinical | Menin–MLL1 inhibitor with improved pharmacokinetics |

**Mechanism of action**: These inhibitors occupy the deep hydrophobic pocket of menin that normally accommodates the N-terminal region of MLL1. By displacing MLL1, they prevent H3K4me3 deposition at HOX loci, leading to transcriptional silencing of HOXA9 and MEIS1. This triggers myeloid differentiation and apoptosis of leukemic cells. Importantly, normal hematopoietic stem cells are less dependent on menin–MLL1, providing a therapeutic window.

**Pharmacogenomic considerations**: The efficacy of menin–MLL1 inhibitors is influenced by:

- **MLL1 (KMT2A) rearrangement status**: Patients with *KMT2A* rearrangements (e.g., t(4;11), t(9;11), t(11;19)) show the highest response rates.
- **NPM1 mutations**: NPM1-mutant AML, which also depends on HOX gene expression, shows sensitivity to menin–MLL1 inhibitors.
- **MEN1 mutation status**: In solid tumors with *MEN1* loss-of-function mutations, menin–MLL1 inhibitors are unlikely to be effective, as menin is absent. However, in tumors with menin overexpression (e.g., MLL-rearranged leukemias), these inhibitors are highly effective.

### 6.2 Menin as a Target in Endocrine Tumors

In MEN1 syndrome, the loss of menin is the driving event, and there is no direct way to restore menin function with small

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)